C型非代償性肝硬変に対するソフォスブビル/ベルパタスビル12週治療の有効性と安全性

DOI Web Site Web Site 参考文献3件

書誌事項

タイトル別名
  • Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection
  • Cガタ ヒダイショウセイ カンコウヘン ニ タイスル ソフォスブビル/ベルパタスビル 12シュウ チリョウ ノ ユウコウセイ ト アンゼンセイ

この論文をさがす

抄録

<p>In this multicenter study, we evaluated the efficacy and safety of 12-week sofosbuvir/velpatasvir (SOF/VEL) treatment. We enrolled 43 consecutive patients with decompensated cirrhosis caused by hepatitis C virus (HCV) infection, 72% and 28% of them were positive for genotype 1 and 2, respectively. At baseline, 79% of the patients were Child-Pugh (CP) class B and 19% were CP class C. All patients completed the 12-week SOF/VEL treatment without any severe adverse events. At post-treatment week 12, 41 patients achieved a sustained virological response (95%), and 21 showed improvement in CP class. The remaining two patients were lost to follow-up. Encephalopathy was a frequent adverse event (16%), but was well-controlled by outpatient management. In conclusion, 12-week SOF/VEL treatment is effective and safe for patients with decompensated cirrhosis caused by HCV infection.</p>

収録刊行物

  • 肝臓

    肝臓 61 (5), 276-278, 2020-05-01

    一般社団法人　日本肝臓学会

参考文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ